Figure 5: A schematic representation of the anti-tumour effects of tivozanib on the GBM cells. | Scientific Reports

Figure 5: A schematic representation of the anti-tumour effects of tivozanib on the GBM cells.

From: Blockade of vascular endothelial growth factor receptors by tivozanib has potential anti-tumour effects on human glioblastoma cells

Figure 5

Tivozanib induced a G2/M cell cycle arrest through up-regulation of p21 and suppression of Aurora kinase A, Aurora kinase B, p-PLK1, cyclin B1 and CDC25C. Tivozanib decreased adhesive and invasive potential of the GBM cells via inhibition of ICAM-1, VCAM-1 and enzymatic levels of MMP-2. Furthermore, tivozanib increased anti-tumour activity of gefitinib on cell growth and induction of apoptosis through down-regulation of the anti-apoptotic proteins survivin and Bcl-2.

Back to article page